Microbial Robotics LLC Information

Since 2009, Microbial Robotics has developed and attracted significant synthetic biology-based technologies. In mid-2016, we will unveil OpenTherapeutics.net. This web portal will crowdsource freely available biopharma technologies to the global community. The open therapeutic opportunities will include bacterial and viral immunotherapy oncolytics, biomarker cancer screens, and pathogenic essential protein targets for developers of new antibiotics. Through hosting global collaboration, the OpenTherapeutics™ model should reduces costs, risks, and timelines for developing and deploying therapeutics into all markets. We also rapidly prototypes genetically enhanced bacteria (BactoBots™), viruses (ViruBots™), and proteome for industrial firms seeking synthetic biology-based products. Collectively known as MicrobialBots™, these synthetic- biology-based products perform functions such as produce chemicals, sense changes, remediate pollutants, and build materials, In 2014 our first biotechnology asset, Pilus Energy, was acquired by a publicly traded company. We are also excited about our genetics rights management (GeRM™) system. GeRM is a consumable that enables the distribution of MicrobialBots (GMOs) without shipping them across borders. As a lock/key consumable, the GeRM molecular keys are added to the MicrobialBot's feedstock. The GeRM keys protects the MicrobialBots against theft or release. If the MicrobialBots are separated from the inert, non-reactive, and non-toxic molecular keys, the MicrorbialBots stop reproducing and begin to die. If you have an interest in gaining a synthetic biology-based rapidly prototyped product, our award-winning team is available to help you gain an entry point into the rapidly expanding synthetic biology industry.